News & Videos - LIPOCINE INC.

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity PR Newswire SALT LAKE CITY, April 11, 2024 LPCN 2401 treatment resulted in statistically significant body composition improvement in men Increased lean mass (LM) by 4.4% and decreased fat mass (FM) by 6.7% Reduced android fat (AF) by 4.1% and increased bone mineral content (BMC) by 2.8% Well-tolerated, adverse events (AEs) similar to placebo Potential for use in combination with...

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis PR Newswire SALT LAKE CITY, March 28, 2024 Met primary and Hepatic Encephalopathy (HE) endpoints in Phase 2 study Increase in Skeletal Muscle Index (SMI) observed at Week 24 was maintained through 52 weeks Participants on placebo increased SMI when switched to LPCN 1148 Fewer Overt Hepatic Encephalopathy (OHE) events and time to first recurrent OHE event was longer while on LPCN 1148 therapy LPCN...

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154 PR Newswire SALT LAKE CITY, March 25, 2024 Company anticipates topline results from this crossover pivotal study late in the second quarter of 2024 SALT LAKE CITY , March 25, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform, today announced that study enrollment is complete and the first cohort of...

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023 PR Newswire SALT LAKE CITY, March 7, 2024 SALT LAKE CITY , March 7, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders, today announced financial results for the year ended December 31, 2023 and provided a corporate update. Neuroactive Steroids Lipocine announced positive topline results from a pharmacokinetics ("PK") pilot bridge...

Lipocine to Present at 36th Annual Roth Conference PR Newswire SALT LAKE CITY, March 6, 2024 SALT LAKE CITY , March 6, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that Dr. Mahesh V. Patel , President and Chief Executive Officer, will participate in a fireside chat and meet with investors at the 36 th Annual Roth Conference, to take place in Laguna Niguel, CA , on March 18 . Presentation...

Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154 PR Newswire SALT LAKE CITY, Feb. 6, 2024 Positive clinical study results confirm 48-hour dosing regimen for the pivotal PK study On track for Q2-24 pivotal study topline results and planned Q4-24 NDA filing SALT LAKE CITY , Feb. 6, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform, today...

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals PR Newswire SALT LAKE CITY, Feb. 2, 2024 SALT LAKE CITY , Feb. 2, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that commercialization of TLANDO® in the U.S. has been transitioned to its licensee Verity Pharma, effective February 1, 2024 , enabling the continuity of patient access to TLANDO. TLANDO...

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada PR Newswire SALT LAKE CITY, Jan. 18, 2024 Lipocine to receive $11 million license fee Up to $259 million in development and commercial sales milestones Tiered royalties on net sales of licensed products up to 18% Commercialization of TLANDO transitions to Verity Pharma effective Feb.1 2024 Lipocine retains all rights for territories outside the United States and Canada , and all non-TRT rights...

Lipocine to Present at Biotech Showcase 2024 PR Newswire SALT LAKE CITY, Dec. 19, 2023 Company Management Will Also Host Meetings at LifeSci Partners Corporate Access Event SALT LAKE CITY , Dec. 19, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that it will present at the Biotech Showcase and host institutional investor and partnering meetings at this event and at a Corporate Access Event...

Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023 PR Newswire SALT LAKE CITY, Nov. 13, 2023 Results demonstrate improvements in sarcopenia and other clinically meaningful outcomes Patients converting from placebo to LPCN 1148 in the ongoing open label extension also showed improvement in sarcopenia SALT LAKE CITY , Nov. 13, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System...

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023 PR Newswire SALT LAKE CITY, Nov. 8, 2023 SALT LAKE CITY , Nov. 8, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform to develop differentiated products, today announced financial results for the third quarter and nine months ended September 30, 2023 , and provided a corporate update....

Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023 PR Newswire SALT LAKE CITY, Nov. 1, 2023 "Late Breaking" abstract scheduled for oral presentation on November 13 SALT LAKE CITY , Nov. 1, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that an abstract on LPCN 1148 has been selected for a late breaking oral presentation at The American Association for the Study of...

Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression PR Newswire SALT LAKE CITY, Oct. 26, 2023 Lipocine and FDA agreed on the acceptance criteria for the pivotal study which enables advancement of LPCN 1154 for postpartum depression (PPD) Company on track to initiate dosing in the pivotal study Q1'24 SALT LAKE CITY , Oct. 26, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by...

Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference PR Newswire SALT LAKE CITY, Oct. 23, 2023 SALT LAKE CITY , Oct. 23, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that it will present and meet with investors at the H.C. Wainwright 7th Annual NASH Investor Conference, taking place virtually October 24, 2023 . Presentation Details Presenter: Dr. Benjamin Bruno,...

Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference PR Newswire SALT LAKE CITY, Sept. 19, 2023 SALT LAKE CITY , Sept. 19, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that Dr. Mahesh Patel, President and Chief Executive Officer, will present and meet with investors at the 2023 Cantor Fitzgerald Global Healthcare Conference to take place September 26th to September...

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023 PR Newswire SALT LAKE CITY, Aug. 10, 2023 SALT LAKE CITY , Aug. 10, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced financial results for the second quarter and six months ended June 30, 2023 , and provided a corporate update. Clinical Program Highlights Neuroactive Steroids Lipocine announced positive topline...

LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis PR Newswire SALT LAKE CITY, July 27, 2023 Met primary endpoint: treatment with LPCN 1148 increased L3 skeletal muscle index (L3-SMI) relative to placebo (P <0.01) Fewer hepatic encephalopathy (HE) events of grade >1 in the LPCN 1148 treatment arm relative to placebo (P < 0.05) More patients on LPCN 1148 reported symptom improvement compared to placebo (P < 0.05) LPCN 1148 was well-tolerated, with AE rates and severities...

Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference PR Newswire SALT LAKE CITY, June 14, 2023 SALT LAKE CITY , June 14, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform to develop differentiated products, today announced that Dr. Mahesh Patel , President and Chief Executive Officer, will present virtually and meet with investors at the H.C....

Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023 PR Newswire SALT LAKE CITY, June 7, 2023 Phase 2 proof-of-concept study of LPCN 1148 in male cirrhotic patients with sarcopenia is fully enrolled with topline 24-week results expected mid-2023 SALT LAKE CITY , June 7, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary technology platform to develop...

Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression PR Newswire SALT LAKE CITY, May 16, 2023 Identified dosing regimen that enables reliance on a single confirmatory pivotal pharmacokinetic (PK) study to establish efficacy for postpartum depression (PPD) and support NDA submission LPCN 1154 treatment was well-tolerated with no hypoxia or sedation-related adverse events Lipocine plans to initiate the...